Kidtrayze (Zinc Chloride, Potassium Iodide, Sodium Selenite, Copper Chloride Dihydrate, Manganese Chloride Tetr)

Zinc chloride supplies zinc ions that act as essential cofactors for numerous enzymes involved in DNA synthesis, immune function and antioxidant defenses, helping restore normal cellular activities that may be compromised in zinc‑deficient states.

The dose of Kidtrayze is determined by the prescribing clinician based on the patient’s specific trace element requirements, clinical condition, and laboratory results. No fixed regimen is provided here.

Safety data for Kidtrayze in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Kidtrayze, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Kidtrayze combines five essential trace elements in a single intravenous formulation, offering a convenient alternative to multiple single‑element preparations. This can simplify dosing and reduce the number of infusion bags required compared with using separate zinc, copper, selenium, iodine or manganese products.

Kidtrayze must be stored at 2‑8 °C, kept refrigerated, protected from light, and should never be frozen or shaken. Follow the manufacturer’s instructions for handling to maintain product stability.

Kidtrayze is administered intravenously, typically as an infusion added to a compatible carrier solution. The exact infusion rate and duration are set by the prescriber according to the patient’s clinical needs and monitoring parameters.

Serious risks include anaphylactic reactions, severe hypersensitivity, copper toxicity, zinc overload, selenium toxicity and acute renal impairment. Patients should be closely monitored for any signs of these adverse events during and after infusion.

Kidtrayze should be avoided in patients with known hypersensitivity to any of its trace element components, in those with severe copper, zinc or selenium toxicity, and in individuals where the risk of infusion‑related reactions outweighs the expected benefit.